1. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study 
Alejandro Llanos-Cuentas, PhD, Martin Casapia, MPH, Raúl Chuquiyauri, PhD, Juan-Carlos Hinojosa, MD, Nicola Kerr, MA, Maria Rosario, PhD, Stephen Toovey, MD, Robert H Arch, PhD, Margaret A Phillips, PhD, Felix D Rozenberg, BA, Jade Bath, BA, Caroline L Ng, PhD, Annie N Cowell, MD, Elizabeth A Winzeler, PhD, David A Fidock, PhD, Mark Baker, PhD, Jörg J Möhrle, PhD, Rob Hooft van Huijsduijnen, PhD, Nathalie Gobeau, PhD, Nada Araeipour, MA, Nicole Andenmatten, PhD, Thomas Rückle, PhD, Stephan Duparc, MD 
The Lancet Infectious Diseases 
Volume 18, Issue 8, Pages (August 2018)
DOI: /S (18)
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1 Trial design and patients ITT=intention-to-treat.
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions